Biocompatibility of subsieve-size capsules versus conventional-size microcapsules

Journal of Biomedical Materials Research - Part A

Volumn 78, Issue 2, 2006, Pages 394-398

  Sakai, Shinji ^a   Mu, Changjun ^a   Kawabata, Kenji ^a   Hashimoto, Ichiro ^a   Kawakami, Koei ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Biocompatibility; Foreign body response; Microcapsule; Microencapsulation; Subsieve size capsule

Indexed keywords

BIODIVERSITY; CELL CULTURE; DENTAL PROSTHESES; FLUID MECHANICS;

FOREIGN BODY RESPONSE; MICROCAPSULES; MICROENCAPSULATION; SUBSIEVE-SIZE CAPSULE;

BIOCOMPATIBILITY;

AGAROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL SIZE; CELL TRANSPLANTATION; CONTROLLED STUDY; CONVENTIONAL SIZE MICROCAPSULE; EPIDIDYMIS FAT; IMPLANT; IN VIVO STUDY; MALE; MICROCAPSULE; MOUSE; NONHUMAN; PERITONEAL CAVITY; RAT; SUBSIEVE SIZE CAPSULE;

ADIPOSE TISSUE; ANIMALS; BIOCOMPATIBLE MATERIALS; CAPSULES; EPIDIDYMIS; EQUIPMENT DESIGN; FOREIGN BODIES; MALE; RATS; SEPHAROSE;

EID: 33745961508     PISSN: 00219304     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.30676     Document Type: Article

References (14)

1. Orive G, Gascon AR, Hernandez RM, Igartua M, Luis Pedraz J. Cell microencapsulation technology for biomedical purposes: Novel insights and challenges. Trends Pharmacol Sci 2003;24:207-210.
2. Chang TM. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 2005;4:221-235.
3. Hauser O, Prieschl Grassauer E, Salmons B. Encapsulated, genetically modified cells producing in vivo therapeutics. Curr Opin Mol Ther 2004;6:412-420.
4. Uludag H, de Vos P, Tresco PA. Technology of mammalian cell encapsulation. Adv Drug Delivery Rev 2000;42:29-64.
5. Sakai S, Kawabata K, Ono T, Ijima H, Kawakami K. Development of mammalian cell-enclosing subsieve-size agarose capsules (<100 μm) for cell therapy. Biomaterials 2005;26:4786-4792.
6. Sakai S, Kawabata K, Ono T, Ijima H, Kawakami K. Preparation of mammalian cell-enclosing subsieve-sized capsules (<100 μm) in a coflowing stream. Biotechnol Bioeng 2004;86:168-173.
7. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980;210:908-910.
8. Rihova B. Immunocompatibility and biocompatibility of cell delivery systems. Adv Drug Delivery Rev 2000;42:65-80.
9. Robitaille R, Pariseau J-F, Leblong FA, Lamoureux M, Lepage Y, Halle J-P. Studies on small (<350 μm) alginate-poly-L-lysine microcapsules. III. Biocompatibility of smaller versus standard microcapsules. J Biomed Mater Res 1999;44:116-120.
10. Koch S, Schwinger C, Kressler J, Heinzen Ch, Rainov NG. Alginate encapsulation of genetically engineered mammalian cells: Comparison of production devices, methods and microcapsule characteristics. J Microencapsul 2003;20:303-316.
11. Sakai S, Kawabata K, Tanaka S, Harimoto N, Hashimoto I, Mu C, Salmons B, Ijima H, Kawakami K. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: A strategy towards chemotherapeutic targeting to tumors. Mol Cancer Ther 2005;4:1786-1790.
12. Pariseau JF, Leblond FA, Harel F, Lepage Y, Halle JP. The rat epididymal fat pad as an implantation site for the study of microcapsule biocompatibility: Validation of the method. J Biomed Mater Res 1995;29:1331-1335.
13. Lum ZP, Krestow M, Tai IT, Vacek I, Sun AM. Xenografts of rat islets into diabetic mice. An evaluation of new smaller capsules. Transplantation 1992;53:1180-1183.
14. Fritschy WM, de Vos P, Groen H, Klatter FA, Pasma A, Wolters GH, van Schilfgaarde R. The capsular overgrowth on microencapsulated pancreatic islet grafts in streptozotocin and autoimmune diabetic rats. Transpl Int 1994;7:264-271.